Aclarion provides update on strength of company positioning following q1 strategic initiatives

Over $20m raised in q1 with nearly $15m cash on hand no debt, no preferred equity, and no warrants with strike prices near the current market nasdaq compliant: fully meets bid price and shareholder equity requirements pivotal clarity trial fully funded with initial interim results expected in q2 2026 broomfield, colo., march 31, 2025 (globe newswire) -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (ai) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following the successful execution of strategic initiatives in q1 2025.
ACON Ratings Summary
ACON Quant Ranking